摘要
目的观察布地奈德喷鼻剂联合盐酸奥洛他定治疗过敏性鼻炎(AR)临床疗效及其对患者血清炎性因子影响。方法将2012年5月至2015年5月接收治疗的82例AR患者作为研究对象,随机平均分为对照组(给予布地奈德)和观察组(给予布地奈德喷鼻剂联合盐酸奥洛他定)。观察并判定AR的治疗效果、相关症状消失的时间(喷嚏、流涕、鼻痒及鼻塞)、相关炎性因子水平[白细胞介素4(IL-4)、白细胞介素8(IL-8)、白细胞介素17(IL-17)、白细胞介素13(IL-13)及肿瘤坏死因子α(TNF-α)]的改善情况及不良反应情况。结果观察组患者治疗总有效率为97.5%,明显高于对照组的85.4%;相关症状(喷嚏、流涕、鼻痒及鼻塞)消失的时间亦均明显短于对照组;治疗后IL-4、IL-8、IL-17、IL-13及TNF-α改善程度均明显优于对照组;不良反应方面两组无显著差异。结论布地奈德喷鼻剂联合盐酸奥洛他定治疗过敏性鼻炎能够改善治疗效果,缓解相关症状且用药安全,具有深入研究的价值。
Objective To study the effects of budesonide and olopatadine hydrochloride on treating allergic rhinitis and its influence on the levels of inflammatory factors.Methods 82 patients with allergic rhinitis were collected as study objects and randomly divided into observation group which was given budesonide and olopatadine hydrochloride,the control group was only give budesonide.Then the curative effect of allergic rhinitis,time of related symptoms disappeared,the levels of inflammatory factors and the adverse actions were observed.Results The allergic rhinitis total effective rate of observation group was 97.5% which was significantly better than that of control group in 85.4%.The related symptoms disappeared time and the levels of inflammatory factors were significantly promoted than that of control group,and no significant differences between the two groups in adverse actions.Conclusion Budesonide and olopatadine hydrochloride can improve the therapeutic effect,shorten symptoms disappeared time,improve the levels of inflammatory factors and worth to next study.
出处
《临床和实验医学杂志》
2016年第24期2449-2451,共3页
Journal of Clinical and Experimental Medicine
